SCHEMBL1648045

SCHEMBL1648045

O=Cc1ccc(OCc2ccccc2)c(C(=O)O)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.73
KDM4E B2RXH2 2/20 0.73
POLB P06746 1/20 0.73
L3MBTL1 Q9Y468 1/20 0.73
FOLH1 Q04609 4/20 0.63
RAB9A P51151 3/20 0.54
NPC1 O15118 2/20 0.54
CYP2C9 P11712 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
MAOA P21397 1/20 0.54
MAOB P27338 1/20 0.54
SMN1; SMN2 Q16637 3/20 0.50
PTGER1 P34995 1/20 0.50
LMNA P02545 1/20 0.49
MCL1 Q07820 1/20 0.48
CTSV O60911 1/20 0.47
CTSL P07711 1/20 0.47
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8847023 0.94 ALDH1A1 (0.64) ALDH1A1KDM4EPOLBL3MBTL1FOLH1
SCHEMBL8846998 0.93 ALDH1A1 (0.64) ALDH1A1KDM4EPOLBL3MBTL1FOLH1
SCHEMBL1315281 0.89 ALDH1A1 (0.59) ALDH1A1KDM4EPOLBL3MBTL1FOLH1
SCHEMBL8847033 0.89 FOLH1 (0.67) ALDH1A1KDM4EPOLBL3MBTL1FOLH1
SCHEMBL6170061 0.89 ALDH1A1 (0.59) ALDH1A1KDM4EPOLBL3MBTL1FOLH1
SCHEMBL2926378 0.88 KDM4E (0.58) ALDH1A1KDM4EPOLBL3MBTL1FOLH1
SCHEMBL852240 0.87 ALDH1A1 (0.59) ALDH1A1KDM4EPOLBL3MBTL1FOLH1
SCHEMBL1647507 0.87 L3MBTL1 (0.57) ALDH1A1KDM4EPOLBL3MBTL1FOLH1
SCHEMBL6809773 0.87 KDM4E (0.71) ALDH1A1KDM4EPOLBL3MBTL1FOLH1
SCHEMBL7906857 0.87 RAB9A (0.61) ALDH1A1KDM4EPOLBL3MBTL1FOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1999048490-A1 ALLOSTERIC INHIBITORS AND ACTIVATORS OF PYRUVATE KINASE ALLOS THERAPEUTICS, INC. (US) 1999-09-30 WO claimed
US-20200347011-A1 DOUBLE-HEADED PROTEASE INHIBITOR UBE INDUSTRIES, LTD. (JP) 2020-11-05 US disclosed
WO-2017050928-A1 PROCESS FOR MANUFACTURING COOKED MEAT PRODUCTS PURAC BIOCHEM BV (NL) 2017-03-30 WO disclosed
EP-2483254-B1 NOVEL COMPOUNDS GLAXO GROUP LTD (GB) 2014-08-13 EP disclosed
US-8778939-B2 Compounds GLAXO GROUP LIMITED (GB) 2014-07-15 US disclosed
EP-2483254-A1 NOVEL COMPOUNDS Glaxo Group Limited (GB) 2012-08-08 EP disclosed
US-20120184553-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2012-07-19 US disclosed
WO-2011038572-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2011-04-07 WO disclosed
EP-1313731-B1 THIAZOLIDINE DERIVATIVES AND ITS USE AS ANTIFUNGAL AGENT UCB SA (BE) 2010-09-29 EP disclosed
EP-1313731-B1 THIAZOLIDINE DERIVATIVES AND ITS USE AS ANTIFUNGAL AGENT UCB SA (BE) 2010-09-29 EP disclosed
US-6740670-B2 SUCH AS 5-(((3-(N-METHYL-N-PHENYLAMINO)CARBONYL-4-(PHENYL-METHOXY)) -PHENYL)METHYLENE)-4-OXO-2-THIOXO-3-THIAZOLIDINE-ACETIC ACID OXFORD GLYCOSCIENCES (UK) LTD. (GB) 2004-05-25 US disclosed
US-20030216453-A1 Thiazolidine derivatives and its use as antifungal agent OXFORD GLYCOSCIENCES (UK) LTD (GB) 2003-11-20 US disclosed
EP-1313731-A1 THIAZOLIDINE DERIVATIVES AND ITS USE AS ANTIFUNGAL AGENT Oxford GlycoSciences (UK) Limited (GB) 2003-05-28 EP disclosed
WO-2002022612-A1 THIAZOLIDINE DERIVATIVES AND ITS USE AS ANTIFUNGAL AGENT OXFORD GLYCOSCIENCES (UK) LIMITED (GB) 2002-03-21 WO disclosed
US-6214879-B1 Allosteric inhibitors of pyruvate kinase VIRGINIA COMMONWEALTH UNIVERSITY 2001-04-10 US disclosed
WO-1999048490-A1 ALLOSTERIC INHIBITORS AND ACTIVATORS OF PYRUVATE KINASE ALLOS THERAPEUTICS, INC. (US) 1999-09-30 WO disclosed
US-5599974-A ALDEHYDE AND ACID CONTAINING COMPOUNDS BOND WITH VALINE, ARGININE, AND LYSINE OF HEMOGLOBIN MOLECULE TO MODIFY MOLECULE CENTER FOR INNOVATIVE TECHNOLOGY (US) 1997-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200347011-A1 DOUBLE-HEADED PROTEASE INHIBITOR TMPRSS15, SPINT2, PRSS2 ALDH1A1 1685/4885KDM4E 4002/4885POLB 3752/4885
US-20030216453-A1 Thiazolidine derivatives and its use as antifungal agent CYP3A7, TAS2R7, OXSR1 ALDH1A1 2527/4885KDM4E 3752/4885POLB 4579/4885
US-20120184553-A1 NOVEL COMPOUNDS LRRK2, PARK7, PINK1 ALDH1A1 4183/4885KDM4E 3000/4885POLB 1889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.